Acquisition Completed
Sensei Biotherapeutics acquisition of Faeth Therapeutics
Announced 18 Feb 2026 · NASDAQ: FTH
Advisers
- Target
- Faeth Therapeutics
- Acquirer
- Sensei Biotherapeutics
- Target based in
- United States
- Buyer based in
- United States
- Completed
- 18 Feb 2026
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Passage Bio and Remix Therapeutics merger Jun 2026 · Biotech
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- Rallybio acquisition of Avenzo Therapeutics Jun 2026 · Biotech
Sources
- 18 Feb 2026 Press release (EX-99.1, exhibit), Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement sec.gov
- 18 Feb 2026 Sidley Represents Sensei Biotherapeutics in Acquisition of Faeth Therapeutics sidley.com
- 18 Feb 2026 Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics cooley.com
